Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab in metastatic solid cancers with DDR gene alterations
NCT04761744Phase 2Unknown
- Sponsor
- Korean Cancer Study Group
- Start
- Jun 2019
- Primary completion
- Mar 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in metastatic solid tumor, sponsored by Korean Cancer Study Group. Status: unknown.
02
Drugs
03
Conditions
metastatic solid tumor
Beyond the preview
Go deeper on NCT04761744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04761744.